Synlett, Table of Contents Synlett 2015; 26(14): 1969-1972DOI: 10.1055/s-0034-1381043 letter © Georg Thieme Verlag Stuttgart · New York Synthesis and Molecular Docking Study of Novel Chromeno-chromenones as Anti-HIV-1 NNRT Inhibitors Hanmant M. Kasralikar Department of Chemistry, Dnyanopasak College, Parbhani-431 401, MS, India Email: bhusare71@yahoo.com , Suresh C. Jadhavar Department of Chemistry, Dnyanopasak College, Parbhani-431 401, MS, India Email: bhusare71@yahoo.com , Sudhakar R. Bhusare* Department of Chemistry, Dnyanopasak College, Parbhani-431 401, MS, India Email: bhusare71@yahoo.com › Author Affiliations Recommend Article Abstract Buy Article All articles of this category Abstract l-Proline has been employed efficiently for the synthesis of chromeno-chromenone derivatives via a one-pot, three component condensation reaction of salicylaldehydes, 4-hydroxy coumarin, and indole or barbituric acid. The simple procedure and good to excellent yields (78–90%) are notable features of the method. The obtained derivatives were studied for their molecular docking as an anti-HIV-1 RT. Keywords Keywordschromeno-chromenone - salicylaldehyde - 4-hydroxycoumarin - l-proline - anti-HIV activity - molecular docking Full Text References References and Notes 1 Fujioka H, Murai K, Kubo O, Ohba Y, Kita Y. Org. Lett. 2007; 9: 1687 2 Dömling A. Chem. Rev. 2006; 106: 17 3 Frankel AD, Young JA. T. Annu. Rev. Biochem. 1998; 67: 1 4 Davey RT. Jr, Dewar RL, Reed GF, Vasudevachari MB, Polis MA, Kovacs JA, Falloon J, Walker RE, Masur H, Haneiwich SE, O’Neill DG, Decker MR, Metcalf JA, Deloria MA, Laskin OL, Salzmant N, Lane HC. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 5608 5 Ragno R, Frasca S, Manetti F, Brizzi A, Massa S. J. Med. Chem. 2005; 48: 200 6 Kostova I, Raleva S, Genova P, Argirova R. Bioinorg. Chem. Appl. 2006; 68274: 1 7 Spino C, Dodier M, Sotheeswaran S. Bioorg. Med. Chem. Lett. 1998; 8: 3475 8 Murakami A, Gao G, Omura M, Yano M, Ito C, Furukawa H, Takahashi D, Koshimizu K, Ohigashi H. Bioorg. Med. Chem. Lett. 2000; 10: 59 9 Xia Y, Yang Z.-Y, Xia P, Hackl T, Hamel E, Mauger A, Wu J.-H, Lee K.-H. J. Med. Chem. 2001; 44: 3932 10 Itoigawa M, Ito C, Tan HT.-W, Kuchide M, Tokuda H, Nishino H, Furukawa H. Cancer Lett. 2001; 169: 15 11 Yamaguchi T, Fukuda T, Ishibashi F, Iwao M. Tetrahedron Lett. 2006; 47: 3755 12 Yamamoto Y, Kurazono M. Bioorg. Med. Chem. Lett. 2007; 17: 1626 13 Rashamuse TJ, Musa MA, Klein R, Kaye PT. J. Chem. Res. 2009; 5: 302 14 Bourinbaiar AS, Tan X, Nagorny R. AIDS 1993; 7: 129 15 Tummino PJ, Ferguson D, Hupe L, Hupe D. Biochem. Biophys. Res. Commun. 1994; 200: 1658 16 Tummino PJ, Ferguson D, Hupe D. Biochem. Biophys. Res. Commun. 1994; 201: 290 17 Vara Prasad JV. N, Para KS, Lunney EA, Ortwine DF, Dunbar JB. Jr, Ferguson D, Tummino PJ, Hupe D, Tait BD, Domagala JM, Humblet C, Bhat TN, Liu B, Guerin DM. A, Baldwin ET, Erickson JW, Sawyer TK. J. Am. Chem. Soc. 1994; 116: 6989 18 Lunney EA, Hagen SE, Domagala JM, Humblet C, Kosinski J, Tait BD, Warmus JS, Wilson M, Ferguson D, Hupe D, Tummino PJ, Baldwin ET, Bhat TN, Liu B, Erickson JW. J. Med. Chem. 1994; 37: 2664 19 Zhou T, Shi Q, Chen CH, Huang L, Ho P, Morris-Natschke SL, Lee KH. Eur. J. Med. Chem. 2012; 47: 86 20 Zhou T, Shi Q, Chen CH, Zhu H, Huang L, Ho P, Lee KH. Bioorg. Med. Chem. 2010; 18: 6678 21 Gong K, Wang H, Luo J, Liu Z. J. Heterocycl. Chem. 2009; 46: 1145 22a Heravi MM, Jani BA, Derikvand F. Catal. Commun. 2008; 10: 272 22b Heravi MM, Sadjadi S, Haj NM, Oskooie HA. Catal. Commun. 2009; 10: 1643 23 Shaabani A, Samadi S, Badri Z, Rahmati A. Catal. Lett. 2005; 104: 39 24 Seifi M, Sheibani H. Catal. Lett. 2008; 126: 275 25 Abdolmohammadi S, Balalaie S. Tetrahedron Lett. 2007; 48: 3299 26 Khurana JM, Kumar S. Tetrahedron Lett. 2009; 50: 4125 27 Khurana JM, Nand B, Saluja P. Tetrahedron Lett. 2010; 66: 5637 28 Karimi AR, Sedaghatpour F. Synthesis 2010; 1731 29 Chen Z, Zhu Q, Su W. Tetrahedron Lett. 2011; 52: 2601 30 Yua T, Yang S, Zhao Y, Zhang H, Han X, Fan D, Qiu Y, Chen L. J. Photochem. Photobiol., A 2010; 214: 92 31 Rao P, Konda S, Iqbal J, Oruganti S. Tetrahedron Lett. 2012; 53: 5314 32 General Procedure for the Synthesis of Chromeno-chromenone Derivatives A mixture of salicylaldehyde (1 mmol), 4-hydroxycoumarin (1 mmol), and l-proline (0.1 mmol) in EtOH (5 mL) was heated to reflux for 6 h. Indole or barbituric acid (1 mmol) was then added to the reaction mixture and reflux continued with stirring for a further 6–8 h (monitoring by TLC). The solid formed was filtered washed with EtOH then with H2O to afford analytically pure product. 33 Representative Analytical Data 9,11-Dibromo-7-(1H-indol-3-yl)-6H,7H-chromeno[4,3-b]chromen-6-one (4c) Brownish solid; yield 90%; mp (280 °C). IR: 3410, 2900, 2350, 2300, 1700, 1600, 1550, 1450, 1400, 1300, 1210, 1150,900, 750, 700 cm–1. 1H NMR (300 MHz, CDCl3): δ = 10.29 (s 1 H, NH), 8.23 (d, 1 H), 8.03 (d, 1 H), 7.67 (t, 2 H), 7.48 (m, 3 H), 7.32 (t, 1 H), 7.21 (d, 2 H), 5.31 (s, 1 H). 13C NMR (300 MHz, CDCl3): δ = 164.53, 158.62, 151.25, 149.00, 147.63, 141.00, 140.87, 135.00, 133.39, 132.52, 130.43, 25.55, 125.06, 124.62, 124.25, 123.87, 117.93, 117.13, 116.57, 111.82, 105.03, 104.00, 103.80, 30.47 cm–1. GC–MS: m/z = 523 [M+]. 9-Bromo-11-iodo-7-(1H-indol-3-yl)-6H,7H-chromeno[4,3-b]chromen-6-one (4g) Brownish solid; yield 85%; mp (282 °C). IR: 3300, 2910, 2870, 1700, 1610, 1490, 1395, 1210, 1050, 850, 820, 710, 600 cm–1. 1H NMR (300 MHz, CDCl3): δ = 10.38 (s, 1 H, NH), 8.14 (dd, 1 H), 8.02 (dd, 1 H), 7.65 (m, 1 H), 7.55 (m, 1 H), 7.52 (m, 1 H), 7.49 (m, 1 H), 7.41 (m, 2 H), 7.34 (d, 1 H), 7.24 (s, 1 H), 7.12 (s, 1 H). 13C NMR (300 MHz, CDCl3): δ = 166.00, 157.12, 153.00, 149.00, 146.00, 143.50, 136.00, 135.39, 134.42, 130.52, 126.85, 125.06, 124.32, 124.25, 124.00, 117.91, 117.12, 116.51, 111.00, 106.00, 101.52, 100.00, 31.00. GC–MS: m/z = 570 [M+]. 5-{9-Chloro-6-oxo-6H,7H-chromeno[4,3-b]chromen-7-yl}-6-hydroxypyrimidine-2,4-(1H,3H)-dione (4m) Brownish solid; yield 89%; mp (89 °C). IR: 3600, 3420, 3380, 2996, 2817, 1702, 1663, 1611, 1566, 1452, 1400, 1215, 1168, 786, 530 cm–1. 1H NMR (400 MHz, DMSO): δ = 12.87 (s, 1 H, OH), 9.89 (s, 1 H, NH), 8.04 (d, 1 H), 7.85 (s, 1 H), 7.60 (s, 1 H), 7.49 (t, 1 H), 7.29 (t, 2 H), 7.18 (d, 1 H), 6.81 (s, 1 H, NH), 5.73 (s, 1 H). 13C NMR (300 MHz, CDCl3): δ = 167.08, 165.76, 163.80, 161.00, 154.29, 152.42, 150.80, 132.36, 131.10, 129.00, 127.63, 127.23, 125.72, 125.12, 120.00, 117.49, 117.12, 115.12, 110.00, 81.50, 29.24. GC–MS: m/z = 410 [M+]. Supplementary Material Supplementary Material Supporting Information